Achieve Digital Dominance with Xentria Inc.'s Expertise

Sponsor: Xentria, Inc. Overall Status: Active - Recruiting. Phase. 1/2. Condition. Sarcoidosis. Lung Disease. Treatment. XTMAB-16 or Placebo ... Cadila Healthcare Ltd. Shanghai Henlius Biotech Inc. Teva Pharmaceutical Industries Ltd. Alvotech; Xentria Inc. Lazuline Biotech Private Limited; Epygen Biotech ... Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Infliximab ... Xentria COO Kirsten Anderson and Meitheal CEO and president of Xentria Tom Shea ... Crain Communications, Inc. All Rights Reserved. Trademark registration by Xentria, Inc. for the trademark XENTRIA. Clinical study for Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Xentria is a pioneering biopharmaceutical company focused on developing biologic and innovative drug therapies. Their investigational drug, XTMAB-16, is a ... View Xentria, Inc. (http://www.xentria.com) location in Illinois, United States , revenue, industry and description. Find related and similar companies as ... Location: Xentria Investigative Site. City/State: Greenville, North ... Xentria, Inc. 224-443-4615 [email protected]. Brief Summary: A phase 1b/2 ...